Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.

Three phase 2b, double-blind, placebo-controlled, randomized efficacy trials have tested recombinant Adenovirus serotype-5 (rAd5)-vector preventive HIV-1 vaccines: MRKAd5 HIV-1 gag/pol/nef in Step and Phambili, and DNA/rAd5 HIV-1 env/gag/pol in HVTN505. Due to efficacy futility observed at the first...

Full description

Bibliographic Details
Main Authors:	Yunda Huang, Dean Follmann, Martha Nason, Lily Zhang, Ying Huang, Devan V Mehrotra, Zoe Moodie, Barbara Metch, Holly Janes, Michael C Keefer, Gavin Churchyard, Merlin L Robb, Patricia E Fast, Ann Duerr, M Juliana McElrath, Lawrence Corey, John R Mascola, Barney S Graham, Magdalena E Sobieszczyk, James G Kublin, Michael Robertson, Scott M Hammer, Glenda E Gray, Susan P Buchbinder, Peter B Gilbert
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4558095?pdf=render

Similar Items

Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-γ secretion with increased HIV-1 infection risk: a cohort-based modeling study.
by: Yunda Huang, et al.
Published: (2014-01-01)

DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials
by: Morgan C, et al.
Published: (2012-09-01)

P14-02. Social impact events in Phambili, the first phase 2B HIV vaccine trial in South Africa
by: Roux S, et al.
Published: (2009-10-01)

Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans.
by: Samuel O Pine, et al.
Published: (2011-04-01)

Benign ethnic neutropenia in a South African population, and its association with HIV acquisition and adverse event reporting in an HIV vaccine clinical trial.
by: Rephaim Mpofu, et al.
Published: (2021-01-01)

P15-08. Did unblinding affect HIV risk behaviour and risk perception in the HVTN503/Phambili study?
by: Moodie Z, et al.
Published: (2009-10-01)

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials.
by: Stephanie Fischinger, et al.
Published: (2021-11-01)

Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity.
by: Barney S Graham, et al.
Published: (2010-08-01)

HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials
by: Volk JE, et al.
Published: (2012-09-01)

Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection
by: Zanele Ditse, et al.
Published: (2020-02-01)

Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens
by: Yunda Huang, et al.
Published: (2022-10-01)

Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants.
by: Nicole Espy, et al.
Published: (2023-01-01)

Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants
by: Nicole Espy, et al.
Published: (2023-01-01)

0A07-01. HIV-specific CD8<sup>+ </sup>T-cells of vaccinees exhibit proliferative and cytotoxic capacities comparable to those of progressors
by: McElrath J, et al.
Published: (2009-10-01)

P17-25. A model for coverage of T-cell HIV vaccines: where are we and where do we need to be?
by: McElrath J, et al.
Published: (2009-10-01)

Mycobacterium tuberculosis infection, immune activation, and risk of HIV acquisition.
by: Rachel A Bender Ignacio, et al.
Published: (2022-01-01)

Mycobacterium tuberculosis infection, immune activation, and risk of HIV acquisition
by: Rachel A. Bender Ignacio, et al.
Published: (2022-01-01)

Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk.
by: Erica Andersen-Nissen, et al.
Published: (2021-03-01)

Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination.
by: Cheng Cheng, et al.
Published: (2012-01-01)

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).
by: Gavin J Churchyard, et al.
Published: (2011-01-01)

Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054).
by: Laurence Peiperl, et al.
Published: (2010-10-01)

Dynamics of viral evolution and CTL responses in HIV-1 infection.
by: Yi Liu, et al.
Published: (2011-01-01)

Cell free HIV-1 virus can infect inner and outer foreskin polarized explants
by: Lemos MP, et al.
Published: (2012-09-01)

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults.
by: Susan P Buchbinder, et al.
Published: (2017-01-01)

Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans.
by: Lue Ping Zhao, et al.
Published: (2020-01-01)

P14-11. Educating community medical providers about HIV vaccine induced seropositivity
by: McElrath M, et al.
Published: (2009-10-01)

Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans
by: Kelly E. Seaton, et al.
Published: (2021-04-01)

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
by: Kenneth H Mayer, et al.
Published: (2017-11-01)

Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials.
by: Daniel B Reeves, et al.
Published: (2020-02-01)

Potential role for neutralizing antibodies in HIV-1 infection
by: J. Mascola
Published: (2015-12-01)

The cat and mouse of HIV-1 antibody escape.
by: John R Mascola
Published: (2009-09-01)

Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies.
by: Michael Vaine, et al.
Published: (2010-11-01)

MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load.
by: Holly Janes, et al.
Published: (2012-01-01)

Buprenorphine Increases HIV-1 Infection In Vitro but Does Not Reactivate HIV-1 from Latency
by: Germán Gustavo Gornalusse, et al.
Published: (2021-07-01)

Does a youth intern programme strengthen HIV service delivery in South Africa? An interrupted time‐series analysis
by: Deanna Tollefson, et al.
Published: (2023-04-01)

Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection.
by: Sarah Auclair, et al.
Published: (2018-02-01)

Trivalent adenovirus type 5 HIV recombinant vaccine primes for modest cytotoxic capacity that is greatest in humans with protective HLA class I alleles.
by: Stephen A Migueles, et al.
Published: (2011-02-01)

Leveraging lessons learned from the COVID-19 pandemic for HIV
by: Thomas Calder, et al.
Published: (2022-08-01)

Access to HIV care in jails: Perspectives from people living with HIV in North Carolina
by: Colleen Blue, et al.
Published: (2022-01-01)

Cognitive Dissonance Identification in the Institutional Setting of the Academic Library
by: Eileen McElrath
Published: (2004-03-01)